TG Therapeutics sells Briumvi for multiple sclerosis.
TG Therapeutics, Inc. (TGTX) is expected to report earnings on Monday, November 2, 2026, after the close. Estimated release time 07:22 ET. Consensus EPS estimate is $0.36.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-05-06 | FY2026 Q1 | $0.23 | $0.14 | -39.1% | $204.92M |
| 2026-02-27 | FY2025 Q4 | $0.35 | $0.16 | -54.3% | $192.57M |
| 2025-08-08 | FY2025 Q2 | $0.32 | $0.19 | -40.6% | $141.15M |
| 2025-03-03 | FY2024 Q4 | $0.08 | $0.16 | +100.0% | $108.19M |
| 2024-11-07 | FY2024 Q3 | $0.03 | $0.03 | +0.0% | $83.88M |
| 2024-08-09 | FY2024 Q2 | $-0.05 | $0.05 | +195.0% | $73.47M |
| 2024-05-06 | FY2024 Q1 | $-0.04 | $-0.07 | -105.0% | $63.47M |
| 2024-02-29 | FY2023 Q4 | $-0.12 | $-0.10 | +16.7% | $43.97M |
TGTX has beaten consensus EPS in 4 of its last 8 reported quarters.
See TGTX on the live calendar →